Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors

Leukemia. 2014 Feb;28(2):457-60. doi: 10.1038/leu.2013.301. Epub 2013 Oct 22.

Authors

T Hideshima¹, R Mazitschek², L Santo³, N Mimura¹, G Gorgun¹, P G Richardson¹, N Raje³, K C Anderson¹

Affiliations

¹ Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
³ MGH Cancer Center, Massachusetts General Hospital, Boston, MA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / toxicity
Apoptosis / drug effects*
Cell Line, Tumor
Endoplasmic Reticulum Stress / drug effects
Histone Deacetylase Inhibitors / pharmacology*
Histone Deacetylase Inhibitors / toxicity
Humans
Multiple Myeloma / metabolism*
Oligopeptides / pharmacology
Signal Transduction / drug effects*

Substances

Antineoplastic Agents
Histone Deacetylase Inhibitors
Oligopeptides
carfilzomib

Grants and funding